Spinnovation launches biologics analysis division

Published: 8-Apr-2011
Finance Analysis Pharmaceutical

Spinnovation Biologics to provide profiling and characterisation of biologics

Spinnovation Analytical, a Dutch contract research organisation, has launched a new division called Spinnovation Biologics, which will provide spent culture media analysis and profiling and characterisation of biologics and biosimilar drugs.

Frederic Girard, chief executive of the Nijmegen-based nuclear magnetic resonance spectroscopy (NMR) specialist, said spent media analysis with Spedia-NMR would be the new company’s core service.

‘Spedia-NMR is unique and can deliver a step-fold increase in throughput and detail over standard methods, in as few as five working days,’ he said.

Spinnovation Biologics will also offer process and product bioanalysis, enabling clients to benefit from advanced insights into cell culture to enhance productivity, scalability, and reliability for QA/QC control, cGMP production and support Quality by Design.

In addition to Spedia-NMR technology, Spinnovation Biologics has a broad spectrum of analysis methods in house, including: LC-MS, LC-NMR, LC-SPE-NMR and LC-SPE-NMR-MS.

See more

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

Read more
To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands

Trending Articles

  1. SCIEX expands integrated software ecosystem with six mass spectrometry workflow collaborations The firm has announced six software collaborations designed to unify instrument control, data processing and compliance within a single analytical environment, with more partnerships set to be revealed at ASMS 2026
  2. BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
  3. Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging
  4. SGS launches GMP-compliant NMR testing for Chinese pharma industry The inspection and certification specialist will now offer nuclear magnetic resonance (NMR) testing for analysis of both drug substances and drug products across China
  5. New Romaco Maximus 400 tablet coater at interpack Ideal for pharmaceutical coatings with a very large weight gain

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Research & Development

Pivot Park and Spinnovation Analytical join forces

To provide analytical solutions at Pivot Park Life Sciences Community, Oss, the Netherlands
Analysis

Spinnovation Biologics predicts bioproduction performance

With the launch of Spedia-Predict
Pharmaceutical

Spinnovation introduces approach to improve biologicals manufacturing processes

Spinnovation technology delivers optimal cell viability and density, with the right safety and quality parameters in a short time frame
Analysis

Spinnovation Biologics offers service choices to meet individual analysis needs for bioprocess optimisation

Unique mix of services delivers essential support for the development and manufacture of biologics
Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Pharmaceutical

Ardena strengthens executive team to drive its next phase of growth

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical

Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities

As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging
Subscribe now